We will help you navigate through the challenges of reimbursement and funding for medical devices and in-vitro diagnostics in Europe

MTRC is an ISO 9001:2015 certified provider of Pan-European reimbursement services and products for Med Tech and IVD industry

MTRC is a unique provider of Pan-European reimbursement services and products for Med Tech and IVD industry

Scope

Coding, payment mechanism, reimbursement tariffs, pathway to create or improve reimbursement situation

 

Project-based on-demand work or >95 off-the-shelf syndicated reports

Countries
19 EU
Availability
Mixed
Scope

Seminars on introduction into market access for medical devices and IVD tests, seminars on reimbursement systems in individual countries (>70 reports)

 

Syndicated analytical reports on the topics of HTA, innovation funding, reimbursement of health apps

Countries
19 EU
Availability
Off-the-shelf
Scope

Subscription service with email alerts about initiated or published health technology assessments of medical devices and in-vitro diagnostic tests from 56 HTA organizations globally

Countries
24 countries globally
Availability
On-demand
Scope

Subscription service with email alerts about key reimbursement developments for medical devices and in-vitro diagnostic tests (codes, DRG system, coverage decisions, innovation funding) from more than 30 organizations in Europe

Countries
14 EU
Availability
On-demand
Scope

Procedure code and DRG applications, other reimbursement applications in selective markets

Countries
Nordics and Russia
Availability
On-demand

Why us?

Analyses from the same vendor for 19 different EU countries
Analyses from the same vendor for 19 different EU countries

Save money and time, get standardized analysis. One of the broadest coverage of EU markets. Our key value proposition is provision of high quality pan-European support

Pharma approach is put aside
Pharma approach is put aside

Work with a company truly specialized in medical devices and diagnostics. Benefit from our topical knowledge from hundreds of projects

Getting results instantly (reports) or within 4-8 weeks (services)
Getting results instantly (reports) or within 4-8 weeks (services)

Make business decisions quickly

17 out of top-30 companies choose MTRC for reimbursement support
17 out of top-30 companies choose MTRC for reimbursement support

Work with a provider who understands the industry’s needs. We served more than 150 clients over the last four years

More than 540 accomplished projects
More than 540 accomplished projects

Work with a provider who has experience in your field. We are ISO 9001:2015 certified and pay a lot of attention to maintain a good quality of services, including >300 internal instructions, regular quality management meetings, strict onboarding and training procedures

Team of 15 full-time employees in 6 countries
Team of 15 full-time employees in 6 countries

Unlike companies with an affiliate model, we do most services with in-house analysts ensuring greater quality, lower cost and predictable outcomes

MTRC is a thought leader in the field of European Med Tech reimbursement
MTRC is a thought leader in the field of European Med Tech reimbursement

MTRC has unique insights into market access through its various activities, including annual syndicated reports on the topics of HTA, innovation funding, reimbursement of digital health, comprehensive newsletter services, unparalleled educational platform and others

To stay up-to-date, we daily monitor developments of reimbursement systems in Europe

Subscribe to our newsletter to get updates every 2nd week

Only less than 10% of the news is reported in the free-of-charge newsletter. Access our paid services "HTA Alerts" and "Reimbursement Alerts" to get full, customized reports from more than 90 reimbursement and HTA organizations globally. Free first issues of both newsletters are available for download

22 Nov 2021
In August, MTRC launched two subscription services with a focus on all published, initiated or ongoing HTA and reimbursement reports and decisions for medical devices, procedures and IVD tests. HTA Alerts is a global service and covers 56 organizations from 24 countries. Reimbursement Alerts is focused on 14 key European countries. All alerts are tailed to the technologies of interest for each client. You can request a free-of-charge 2-month sample of reporting for both services

26

Nov 2021

In early-mid November 2021, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for two new cardiovascular technologies (Revivent TC™ by BioVentrix and Trilogy™ Heart Valve System by JenaValve Technology) in heart failure, and aortic valve insufficiency and stenosis, respectively.

25

Nov 2021

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in October 2021. More than 20 recommendations were published in relation to the registration, modification of registration conditions, renewal of registration of devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular, peripheral vascular, neurovascular and neuromodulation, and other groups of devices, as well as medical aids.

24

Nov 2021

In October 2021, the Scottish Health Technology Group released two Innovative Medical Technology Overviews for e-health technologies. The topics were asynchronous digital dermatology appointment service (DDAS) and the Dxcover™ Brain Cancer Liquid Biopsy. Regarding DDAS, the authors concluded that the Scottish health boards should provide more data to allow for further performance and economic analyses of the DDAS. Regarding Dxcover™, the SHTG concluded that it was cost-effective, but further work to confirm its accuracy, effectiveness, safety, and cost-effectiveness is required.

23

Nov 2021

In late October 2021, the Treatment Council (Behandlingsråd) published three topics chosen for developing the so-called major analyses (større analyser) in 2022. The selected topics include patient-centered diabetes technology, hand-held focused ultrasound in emergency medicine, and artificial intelligence as decision support for colonoscopy.

Our two core services are the provision of off-the-shelf and on-demand reimbursement analysis and the development of reimbursement strategy for medical devices in 19 European countries

Analysis

Reimbursement

  • Availability of procedure / reimbursement code
  • Reimbursement mechanism (diagnosis-related group or fee for service)
  • Availability of add-on reimbursement
  • Availability of innovation funding
  • Reimbursement tariffs

National funding

Willingness to pay for technology, based on:

  • Statements from national commissioners (e.g., NHS England)
  • Health Benefit Catalogues (e.g. in Spain, LEA Levels in Italy)
  • National clinical guidance (e.g. NICE in the UK, Haute Autorité de Santé in France, Socialstyrelsen in Sweden)
  • National health technology assessments in connection with reimbursement decisions (e.g. NICE for Technology Appraisal in the UK, Haute Autorité de Santé in France)
  • Specific funding frameworks (e.g., “New method” in Norway)
Strategy

Reimbursement strategy

Pathway to get reimbursement:

  • Overview of drivers and barriers for adoption
  • Overview of key reimbursement and funding pathways (including state-sponsored studies and innovation funding)
  • Detailed presentation of individual pathways (process, stakeholders, requirements, timelines)
  • Action plan

Check our specific propositions for: Med Tech industry, IVD industry, Investors

Our services cover 19 European countries, including Austria, Belgium, Czech Republic, Denmark, England, Finland, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, Switzerland and Turkey

We provide services for major types of medical technologies

Implantable devices

Interventional procedures

Non-in­ter­ven­tional procedures

In-vitro diagnostic tests

Medical aids

Our analytical team has worked on hundreds of reimbursement projects within different clinical and technological areas, including heart valve replacement, minimally invasive and open heart surgery, coronary, cerebral and peripheral stenting, coronary diagnostic and imaging techniques (fractional flow reserve, intravascular ultrasound), coronary, cerebral and peripheral vascular thrombectomy, implantable and extracorporeal ventricular assist devices, clinic- and home-based dialysis, extracorporeal membrane oxygenation, apheresis, obesity surgery, hernia and reconstruction surgery, tissue products and skin reconstruction surgery, negative wound pressure therapy and medical bandages, neurostimulators for different indications, cell therapy, rehabilitation devices, devices for minimally invasive and open spine surgery, embolization procedures, glucose monitoring, use of fusidial markers, radiotherapy, endoscopy and more

Confidence in results

MTRC is ISO 9001:2015 certified organization (with the United Kingdom Accreditation Service, UKAS). We have established numerous procedures and services to ensure the high relevance and precision of our analysis in order to successfully guide your business decisions:

  • Standard Operating Procedures and Work Instructions
  • Access to official coding and DRG manuals, tariff lists and grouping software
  • A team comprised of experienced Clinical Coders with a medical background
  • Quick access to health authorities to address uncertainties
  • Ongoing research program to get insights from payer and provider interviews
  • All reports are reviewed by the CEO before release

Check out our database of the off-the-shelf reimbursement reports for medical technologies in 11 European countries

Released reports:

  • 3D conformal radiation therapy
  • Ablation of heart tissue for atrial fibrillation
  • Angioplasty of arteries of lower extremities for peripheral artery disease
  • Atherectomy for peripheral artery disease
  • Bariatric surgery
  • Biologic and synthetic skin substitutes
  • Brachytherapy
  • Breast reconstruction
  • Capsule endoscopy
  • Cardiac pacemakers
  • Cardiac resynchronization therapy
  • Cholecystectomy
  • Coronary artery bypass grafting
  • Coronary imaging and diagnostic procedures
  • Coronary percutaneous revascularization procedures
  • Deep brain stimulation
  • Diagnostic endoscopic procedures on the lower gastrointestinal tract
  • Diagnostic endoscopic procedures on the upper gastrointestinal tract
  • Endoscopic biliary procedures
  • Health apps
  • Hemodialysis for acute kidney injury
  • Hernia repair
  • Embolic Protection Devices during percutaneous cardiac procedures (PCI and TAVI)
  • Endovascular repair (EVAR) of abdominal aortic aneurysm (AAA)
  • Extra-corporeal membrane oxygenation (ECMO) for pulmonary and cardiac failure
  • Image-guided radiotherapy
  • Implantable cardioverter defibrillators (ICDs)
  • Intensity modulated radiotherapy (IMRT)
  • Left atrial appendage occlusion
  • Mechanical ventilzation
  • Mechanical thrombectomy for acute ischemic stroke
  • Minimally-invasive endoluminal procedures for gastro-esophageal reflux disease (GERD)
  • Open replacement of heart valves (all valves)
  • Percutaneous ablation procedures for diseases of lung, prostate, kidney, liver and bone
  • Percutaneous procedures for deep vein thrombosis
  • Proton Therapy
  • Robotic surgery interventions
  • Selective internal radiation therapy (SIRT)
  • Spinal cord stimulation
  • Stereotactic body radiation therapy
  • Stereotactic Radiosurgery
  • Surgical and endovascular treatment of brain aneurysm
  • Transcatheter aortic valve implantation (TAVI)
  • Transcatheter mitral valve leaflet repair using mitral clips for mitral regurgitation
  • Use of intra-aortic balloon pump (myocardial infarction and unstable angina, complicated by cardiogenic shock)
  • Vascular access for long-term use: AV fistula and AV graft
  • Ventricular assist devices for circulatory support
  • Volumetric modulated arc therapy (VMAT)

Ongoing reports:

  • Companion diagnostic tests for breast cancer
  • Biologic and synthetic skin substitutes